Introduction
You have been getting your cholesterol checked for years. Every annual physical, the same panel: total cholesterol, LDL, HDL, triglycerides. The numbers go up and down. Your doctor adjusts your statin dose. You try to eat less saturated fat. The cycle repeats.
But here is a disturbing fact that the 2026 ACC/AHA dyslipidemia guidelines https://lyproc.com/new-lp-a-testing-guidelines-2026/
have finally forced into the open: you can have perfectly normal LDL cholesterol and still have a heart attack.
How is this possible? Because the standard lipid panel does not measure the two factors that may matter most: lipoprotein(a) [Lp(a)] and apolipoprotein B (ApoB).
These two tests tell the real story of your cardiovascular risk—a story that LDL alone cannot reveal. The 2026 guidelines now recommend Lp(a) testing for all adults and ApoB testing for many. If your doctor has not yet ordered them, this article will help you understand why you should ask.
If your levels have come back high, this article will help you understand what the numbers mean—and what you can do about them beyond taking a statin.
The Standard Lipid Panel: What It Tells You (and What It Misses)
The standard lipid panel measures four things:
- Total cholesterol: The sum of all cholesterol in all lipoprotein particles.
- LDL cholesterol: The cholesterol carried in low-density lipoprotein particles. Called “bad” cholesterol.
- HDL cholesterol: The cholesterol carried in high-density lipoprotein particles. Called “good” cholesterol.
- Triglycerides: The storage form of fat, carried primarily in VLDL particles.
This panel has been the foundation of cardiovascular risk assessment for over 50 years. It is inexpensive, widely available, and supported by decades of research linking high LDL to increased heart attack risk.
But the standard panel has a critical blind spot: it measures the amount of cholesterol carried inside particles. It does not measure the number of particles, and it does not identify the most dangerous type of particle.
This is like assessing the traffic on a highway by weighing the total cargo instead of counting the number of trucks. More trucks mean more chances for a collision—even if each truck is carrying a light load.
What Lp(a) Reveals That LDL Cannot
Lipoprotein(a)—pronounced “lipoprotein little a”—is a specific type of LDL particle with an extra protein called apolipoprotein(a) attached to its surface.
This extra protein makes Lp(a) uniquely dangerous for two reasons:
- Lp(a) is sticky.
Apolipoprotein(a) has lysine-binding sites that allow the particle to adhere to damaged areas of the artery wall. While ordinary LDL particles may float past a healthy endothelium, Lp(a) actively seeks out and binds to areas of vascular injury. - Lp(a) promotes clotting.
Apolipoprotein(a) is structurally similar to plasminogen, a protein involved in dissolving blood clots. By competing with plasminogen, Lp(a) may interfere with the body’s natural clot-busting mechanisms, increasing the risk of a thrombotic event—a heart attack or stroke.
A 1990 US patent, based on gel electrophoresis of human arterial plaque, proved that the primary component of atherosclerotic plaque is Lp(a)—not ordinary LDL cholesterol.
The 2026 ACC/AHA guidelines now recommend universal Lp(a) screening for all adults at least once in their lifetime. This is a Class I recommendation—the strongest level of evidence. The threshold for elevated risk is 125 nmol/L (approximately 50 mg/dL). Levels above 250 nmol/L are associated with at least a two-fold increased lifetime risk of heart attack or stroke.
Approximately one in five people worldwide has elevated Lp(a). Yet fewer than 1% have ever been tested. You are far more likely to have high Lp(a) than high LDL. And unlike LDL, statins do not lower Lp(a). In some patients, statins may modestly raise it.
What ApoB Reveals That LDL Cannot
If Lp(a) identifies the most dangerous type of particle, ApoB counts the total number of dangerous particles.
Every atherogenic lipoprotein particle—VLDL, IDL, LDL, and Lp(a)—contains exactly one molecule of apolipoprotein B. Measuring ApoB is therefore equivalent to counting the total number of these particles in your blood.
Why does particle number matter more than cholesterol mass? Because atherosclerosis is driven by particles entering the artery wall. Each particle that crosses the endothelium carries cholesterol with it. More particles mean more cholesterol deposited, even if each particle contains relatively little cholesterol.
Two people can have the same LDL cholesterol of 100 mg/dL. One may have large, cholesterol-rich LDL particles numbering 800 nmol/L of ApoB. The other may have small, dense, cholesterol-poor particles numbering 1,400 nmol/L of ApoB. The second person is at nearly twice the risk—yet their standard lipid panel looks identical.
The 2026 guidelines now recommend ApoB testing for people with diabetes, metabolic syndrome, high triglycerides, or established cardiovascular disease. Target levels vary by risk:
- Intermediate risk: ApoB below 90 mg/dL
- High risk: ApoB below 80 mg/dL
- Very high risk: ApoB below 70 mg/dL
How Lp(a) and ApoB Work Together to Tell the Full Story
When you measure both Lp(a) and ApoB, a complete picture of your atherogenic particle burden emerges.
Consider three patients. All three have the same LDL cholesterol of 110 mg/dL. Their doctors consider them at similar risk.
- Patient A: ApoB 85 mg/dL, Lp(a) 10 mg/dL. This patient has a relatively low number of particles and low Lp(a). True risk: below average.
- Patient B: ApoB 110 mg/dL, Lp(a) 15 mg/dL. This patient has a high number of particles, largely driven by small, dense LDL. True risk: significantly elevated.
- Patient C: ApoB 95 mg/dL, Lp(a) 80 mg/dL. This patient has a moderate number of particles, but a large proportion of them are the highly dangerous Lp(a) variety. True risk: very high, despite the relatively normal ApoB.
The standard lipid panel would not distinguish among these three patients. Lp(a) and ApoB testing reveals their true risk profiles—and allows for appropriately tailored treatment.
What to Do If Your Lp(a) or ApoB Is High
The conventional approach to elevated Lp(a) and ApoB is limited.
For high ApoB, statins are the first line. They reduce LDL and ApoB by 30–50%, depending on the drug and dose. If statins are insufficient, ezetimibe or PCSK9 inhibitors may be added.
For high Lp(a), the options are fewer. Statins do not lower Lp(a). PCSK9 inhibitors reduce it by about 20–30%. New drugs targeting Lp(a) production directly—pelacarsen and olpasiran—are in clinical trials but not yet approved. Patients with high Lp(a) are often told that it is genetic, that lifestyle changes will not help, and that there is nothing specifically they can do.
This is incomplete. It treats Lp(a) and ApoB as enemies to be suppressed rather than understanding why they are elevated in the first place.
The Root-Cause Perspective: Why Are These Numbers High?
As I explain in my book Reverse Heart Disease: No Lifelong Suffering, Lp(a) is not a random genetic error. It is a repair particle. Your liver produces it in response to structural weakness in your artery walls.
When your arteries lack the nutrients they need to maintain strong collagen—specifically vitamin C, lysine, and proline —the vessel wall develops microscopic cracks. Your body deploys Lp(a) to patch those cracks, just as it would send platelets and fibrin to patch a wound on your skin. Over decades, these Lp(a) patches accumulate into plaque.
High Lp(a) is not the cause of your disease. It is evidence that your artery walls need repair.
ApoB, similarly, is not a random metabolic error. It reflects the liver’s production of lipoprotein particles. When the liver is burdened by nutrient deficiencies, oxidative stress, and metabolic dysfunction—particularly from excess refined carbohydrates and industrial seed oils—it overproduces VLDL particles, which eventually become LDL and contribute to a high ApoB.
The solution is not simply to block an enzyme or inhibit a gene. The solution is to:
- Provide the nutrients your arteries need to repair their collagen structure—vitamin C, lysine, and proline.
- Provide the nutrients your liver needs to regulate lipoprotein production—B vitamins, magnesium, choline, omega-3 fatty acids.
- Remove the metabolic stressors that drive VLDL overproduction—refined carbohydrates, industrial seed oils, and other processed foods.
When you do this, the signals that drive Lp(a) and ApoB production begin to diminish. The numbers may normalize not because you suppressed them with drugs, but because your body no longer needs to produce so many particles.
The Tests to Ask For
If you have not yet had your Lp(a) and ApoB measured, here is what to request at your next blood draw:
| Test | What It Measures | Recommended For |
| Lipoprotein(a) | The concentration of Lp(a) particles in your blood. | All adults, at least once in a lifetime (per 2026 guidelines). |
| Apolipoprotein B | The total number of atherogenic particles. | People with diabetes, metabolic syndrome, high triglycerides, or established cardiovascular disease (per 2026 guidelines). |
Together with your standard lipid panel, these two tests provide the most complete picture of your cardiovascular risk currently available.
A Personal Word
I learned the importance of looking beyond standard cholesterol the hard way—through my own heart disease.
In 2010, I was diagnosed with two coronary artery blockages above 80%. My cholesterol numbers were not extraordinarily high. But my arteries were failing. The standard panel had missed something.
When I dug into the research, I found the Lp(a) story. I found the 1990 patent proving plaque is Lp(a), not ordinary LDL. I found the connection to vitamin C deficiency and collagen weakness. I realized that my arteries had been starved of the nutrients they needed for years.
I addressed the root cause. Today, at 75, I take no heart medications. My heart functions well.
You may not be able to control whether your doctor orders these tests. But you can ask. And if your Lp(a) or ApoB comes back high, you now know there is something you can do—beyond waiting for the next drug to be approved.
The real story of your heart risk is told by two numbers most doctors still do not test. Ask for them. Understand them. Act on them.
Dr. Balaram Dhotre is a PhD medicinal chemist, cellular nutritionist, and the author of Unraveling the Root Cause of Chronic Diseases and Reverse Heart Disease: No Lifelong Suffering. He writes at lyproc.com to help people understand the true root cause of chronic illness and reclaim their health.
[Click here to get your copy of Reverse Heart Disease: No Lifelong Suffering on Amazon]
————————————————————————————————————————————–
Books By Dr Balaram Dhotre
————————————————————————————————————————
Links on Amazon
Unraveling The Root Cause of Chronic Diseases:
Reverse Heart Disease: No Lifelong Suffering
—————————————————————————————————————————-